Amgen's Virus-Based Cancer Drug Wins Green Light From EU Regulators

Drug regulators from the European Medicines Agency have issued a recommendation for the approval of Amgen's virus-based cancer treatment, T-Vec. If approved by the European Commission, T-Vec would become the first drug in a class of novel agents called oncolytic immunotherapies.